Optical Imaging Market

How big is Optical Imaging Market in 2026?

The global optical imaging market is estimated at USD 1.5 billion in 2025 and is expected to reach USD 1.6 billion in 2026. Demand for optical imaging systems is forecast to grow at a CAGR of 4.5% between 2026 and 2036, taking the market to USD 2.5 billion by 2036. According to FMI analysis, optical coherence tomography is expected to hold the largest share, at 39.4% of 2026 technology sales.

Eye clinics and hospitals buy most optical imaging systems, since retinal damage from diabetes needs repeated scans to guide treatment. Demand for retinal imaging grows with that patient base, which keeps expanding each year. A case in point is the International Diabetes Federation estimate that 589 million adults aged 20 to 79 are living with diabetes, with the number projected to reach 853 million by 2050 [1]. Treatment volumes show the same growth, as US net sales of EYLEA HD rose 52% to USD 596 million in the second quarter of 2026 [2]. FMI analysis shows that each injection decision still depends on an OCT scan, which keeps clinics buying new systems. Adoption of multimodal devices is also growing, and ZEISS introduced the ALTA DUO 300 in September 2026, combining OCT and fundus photography within a single imaging device [3]. Consequently, clinics have a clear reason to replace older single-mode equipment.

Table 1: Optical Imaging Market Size and Forecast (USD billion), 2025 to 2036

Market size and forecast	Value
2025 market size	USD 1.5 billion
Estimated market size in 2026	USD 1.6 billion
Projected market size by 2036	USD 2.5 billion
CAGR (2026 to 2036)	4.5%
Added sales, 2026 to 2036	USD 0.9 billion

Key Market Trends & Insights

• By technology: OCT systems are set to capture 39.4% of 2026 sales, as cross-sectional retinal scans are now routine in diagnosing macular disease and glaucoma.
• By application: Oncology leads application demand at an estimated 33.8% of 2026 sales, with optical methods helping surgical teams see tumour margins and tissue changes.
• By end user: Hospitals, holding 38% of 2026 sales, remain the largest end user, given that oncology, ophthalmology and research imaging are concentrated in large centres.

Regional Highlights

• Fastest-growing country: India is expected to grow fastest, at a CAGR of 5.9% from 2026 to 2036, as diabetic eye screening and new private eye hospitals expand OCT installations.
• Growth across other countries: Demand in the ASEAN countries is set to rise at a 5.7% CAGR, a little ahead of China at 5.3%. Spain is likely to grow at 4.6%, close to Germany at 4.2%. Growth in the United States is put at 3.8%, and Japan has the slowest rate at 3.6%.

Large ophthalmic groups that can fund new platforms now dominate device supply in optical imaging. Carl Zeiss Meditec reported fiscal 2024/25 revenue of EUR 2,228 million, with the Ophthalmology segment up 8.5% to EUR 1,724 million [4]. Sales of OCT and fundus systems gain from this steady clinic investment, which supports replacement cycles. Product pipelines are also widening at the main eye care suppliers. At ARVO 2026, Heidelberg Engineering showed a multimodal imaging platform with ultra-high resolution OCT and a SPECTRALIS system with 250 kHz scan speed pending 510(k) clearance [5]. Faster scanners shorten patient visits, so clinics with heavy volumes gain a strong reason to upgrade.

Demand for retinal scans is tied closely to the drugs that the scans help to guide. Regeneron reported that US EYLEA net sales fell 45% to USD 412 million in the second quarter of 2026, and EYLEA HD grew to USD 596 million [2]. A shift to longer-acting doses changes visit patterns, though each injection decision still depends on an OCT scan. Software is becoming a second source of value for OCT makers. ZEISS received a CE mark in August 2025 for CIRRUS PathFinder, which uses deep learning to identify abnormal macular OCT B-scans automatically [6]. Automated reading lets busy clinics handle more scans per day, which raises the value of installed OCT units.

Use of optical imaging in oncology is the newest growth area outside the eye. The American Cancer Society projects about 2,114,850 new cancer cases in the United States in 2026 [7]. A large case load creates demand for tools that help surgical teams check tumour margins in the operating room. Perimeter Medical Imaging AI submitted a PMA application for the B-Series OCT system after a 206-patient randomised trial in breast-conserving operations [8]. Approval of intraoperative OCT would open a new hospital segment, though adoption will depend on clear reductions in repeat operations.

Table 2: Supporting Industry Indicators for the Optical Imaging Market, 2024 to 2026

Indicator	Data point	Why it matters	Source
Adults with diabetes	589 million adults aged 20 to 79 live with diabetes, projected to reach 853 million by 2050.	Diabetic eye disease drives retinal screening.	[1]
Undiagnosed diabetes	252 million adults with diabetes are not aware of the condition.	Screening programmes can find patients needing eye imaging.	[1]
Anti-VEGF treatment	US EYLEA HD net sales rose 52% to USD 596 million in Q2 2026.	Retinal injections are guided by OCT scans.	[2]
Older anti-VEGF dosing	US EYLEA net sales fell 45% to USD 412 million in Q2 2026.	Longer-acting doses change imaging visit patterns.	[2]
Ophthalmic device sales	Carl Zeiss Meditec Ophthalmology revenue rose 8.5% to EUR 1,724 million in fiscal 2024/25.	Clinic investment supports OCT replacement.	[4]
Supplier outlook	Carl Zeiss Meditec expects revenue to rise by a mid-single-digit percentage in fiscal 2025/26.	Supplier guidance frames near-term device demand.	[4]
AI OCT reading	ZEISS received a CE mark for CIRRUS PathFinder in August 2025.	Automated reading raises scan throughput.	[6]
Multimodal device	ZEISS introduced the ALTA DUO 300 combining OCT and fundus photography in September 2026.	Combined units encourage replacement of older systems.	[3]
Scan speed	Heidelberg Engineering showed a SPECTRALIS with 250 kHz scan speed at ARVO 2026, pending 510(k) clearance.	Faster scanning shortens clinic visits.	[5]
US cancer cases	About 2,114,850 new cancer cases are projected in the United States in 2026.	Cancer volumes create demand for margin imaging.	[7]
Intraoperative OCT	Perimeter Medical Imaging AI filed a PMA for the B-Series OCT after a 206-patient randomised trial.	Approval would open an oncology operating-room segment.	[8]

Demand Intensity Analysis

The optical imaging market size can first be set against ophthalmic device sales at the largest supplier. Carl Zeiss Meditec reported Ophthalmology segment revenue of EUR 1,724 million in fiscal 2024/25 [4]. The market, estimated at USD 1.5 billion in 2025, is smaller than that one segment, at less than 0.87 times the segment value whenever one euro buys more than one dollar. The gap comes from a difference in scope, since the ZEISS segment includes surgical devices, lenses and consumables, and the market estimate covers optical imaging systems across all uses. A global imaging market smaller than one supplier's eye care business shows how specialised the optical imaging category is.

The leading technology segment can be set against the drugs that OCT supports. OCT systems, with 39.4% of the 2026 estimate, represent close to USD 630.4 million. US net sales of EYLEA HD reached USD 596 million in the second quarter of 2026 alone [2]. Global OCT sales for a year therefore equal about 1.1 times one quarter of US sales of a single retinal drug. Imaging is a small cost next to the therapy that the scans guide.

Diabetes prevalence data help test whether the 4.5% CAGR is reasonable. The International Diabetes Federation projects adults with diabetes to rise from 589 million to 853 million by 2050, about 1.4% a year [1]. Set against that pace, the forecast implies about 3 percentage points of annual growth from wider screening, AI software and new uses such as oncology. Carl Zeiss Meditec also expects mid-single-digit revenue growth for fiscal 2025/26, which is broadly consistent with the market CAGR [4]. Together, these benchmarks indicate a forecast grounded in patient growth plus moderate gains in adoption.

Patient counts give a final measure of scale. Dividing the 2026 estimate by 589 million adults with diabetes gives about USD 2.7 per adult [1]. Oncology at 33.8% of the 2026 estimate equals about USD 540.8 million, or about USD 256 per new US cancer case projected for 2026 [7]. Both ratios overstate spend per patient in the stated groups, since the market is global and serves many other uses, though the low values show ample room for wider adoption.

Table 3: Demand Intensity Metrics for the Optical Imaging Market, 2024 to 2026 Data Against 2025 and 2026 Market Values

Demand intensity metric	Value	Basis
Carl Zeiss Meditec Ophthalmology revenue, fiscal 2024/25	EUR 1,724 million	Carl Zeiss Meditec, fiscal 2024/25 results
Market value relative to the ZEISS Ophthalmology segment	Below 0.87 times	Calculated from ZEISS fiscal 2024/25 segment revenue and the 2025 market value
OCT segment value, 2026	USD 630.4 million	Calculated as 39.4% of the 2026 market value
EYLEA HD US net sales, Q2 2026	USD 596 million	Regeneron, second quarter 2026 results
OCT segment as a multiple of quarterly EYLEA HD US sales	About 1.1 times	Calculated from Regeneron Q2 2026 sales and the 2026 OCT segment value
Growth in adults with diabetes to 2050	About 1.4% a year	Calculated from International Diabetes Federation figures of 589 million and 853 million
Implied annual growth from screening, software and new uses	About 3 percentage points	Calculated from the 4.5% CAGR and the diabetes growth rate
Market value per adult with diabetes, 2026	About USD 2.7	Calculated from International Diabetes Federation figures and the 2026 market value
US new cancer cases, 2026	About 2,114,850	American Cancer Society, Cancer Statistics 2026
Oncology segment value per US new cancer case, 2026	About USD 256	Calculated from American Cancer Society projections and the 2026 oncology segment value

Analyst Perspective

“Optical imaging is a mature eye care business with a newer oncology business growing alongside. AI reading and multimodal devices will drive replacement in clinics, and intraoperative imaging could add a hospital segment within the decade. Suppliers that pair hardware with validated software will defend prices best.”

- Anurag Sharma, Principal Consultant, Future Market Insights.

How is the optical imaging market segmented?

The market is segmented into technology, application, end user, and region. Optical coherence tomography is expected to lead technology with 39.4% share in 2026, and oncology leads application with an estimated 33.8%.

By technology: optical coherence tomography (OCT), terahertz tomography, Raman spectroscopy, photo-acoustic imaging, diffuse optical tomography (DOT), super-resolution microscopy, and hyper-spectral imaging.

By application: oncology, dermatology, drug development, dentistry, neurology, and ophthalmology.

By end user: hospitals, diagnostic imaging centers, research laboratories and academic institutes, and pharmaceutical and biotechnology companies.

By region: North America, Latin America, Western Europe, Eastern Europe, East Asia, South Asia and Pacific, and Middle East and Africa.

Why does optical coherence tomography lead optical imaging by technology?

Optical coherence tomography is expected to lead technology sales with 39.4% share in 2026, ahead of hyper-spectral imaging at an estimated 14.2%.

Table 4: Technology Share for the Optical Imaging Market (percentage share), 2026

Technology	Estimated Share (2026)
Optical Coherence Tomography (OCT)	39.4%
Hyper-spectral Imaging	14.2%
Photo-acoustic Imaging	11.6%
Raman Spectroscopy	10.3%
Super-resolution Microscopy	9.8%
Diffuse Optical Tomography (DOT)	8.4%
Terahertz Tomography	6.3%
Total	100.0%

Table 5: Technology Leadership and Market Growth for the Optical Imaging Market (segment and CAGR percentage), 2026 to 2036

Metric	Value
Global CAGR (2026 to 2036)	4.5%
Leading Segment	Optical Coherence Tomography (OCT)

OCT leads with 39.4% of 2026 sales, as micron-level cross-sections of the retina are now standard in every retina and glaucoma clinic. Hyper-spectral imaging holds about 14.2%, photo-acoustic imaging 11.6% and Raman spectroscopy 10.3%, mostly in research and surgical guidance. Super-resolution microscopy, diffuse optical tomography and terahertz tomography share the remaining 24.5%. Software is extending the lead of OCT over other methods. ZEISS said CIRRUS PathFinder uses proprietary deep learning algorithms to identify abnormal macular OCT B-scans [6]. AI support raises the value of each installed scanner, and OCT is expected to keep the lead through 2036. Related nuclear and optical tracers grow faster, with the molecular imaging market projected at a 7.5% CAGR from 2026 to 2036.

• OCT systems include spectral-domain and swept-source scanners, OCT angiography and anterior segment OCT.
• Scan speed is driving the next upgrade cycle. Heidelberg Engineering showed a SPECTRALIS with 250 kHz scan speed at ARVO 2026, pending 510(k) clearance [5]. Faster acquisition improves OCT angiography quality, which encourages clinics to replace older units.

Why does oncology lead optical imaging by application?

With 33.8% of 2026 application sales, oncology ranks first, and ophthalmology is second on about 24.6%.

Table 6: Application Share for the Optical Imaging Market (percentage share), 2026

Application	Estimated Share (2026)
Oncology	33.8%
Ophthalmology	24.6%
Neurology	13.1%
Dermatology	11.2%
Drug Development	10.4%
Dentistry	6.9%
Total	100.0%

Oncology represents 33.8% of 2026 sales, since optical methods help detect tumours, map margins and study tissue in cancer research. Ophthalmology is close behind at about 24.6%, neurology holds 13.1%, dermatology 11.2%, drug development 10.4% and dentistry 6.9%. Cancer case loads in the United States keep rising. The American Cancer Society projects about 626,140 cancer deaths in the United States in 2026 [7]. A heavy cancer burden keeps hospitals investing in better tissue imaging, and FMI projects oncology to remain the largest application through 2036. Diagnostic spend is broad, with the cancer diagnostics market forecast to grow at an 8.5% CAGR from 2026 to 2036.

• Oncology uses include intraoperative margin assessment, endoscopic imaging and tumour research microscopy.
• Blood-based tests are a competing route to early detection. The liquid biopsy market is projected to grow at a 14.8% CAGR from 2026 to 2036, which puts pressure on imaging to prove value at the surgical stage.

Why do hospitals lead optical imaging by end user?

Hospitals are expected to lead end user sales with 38% share in 2026, ahead of diagnostic imaging centers at an estimated 24.5%.

Table 7: End User Share for the Optical Imaging Market (percentage share), 2026

End User	Estimated Share (2026)
Hospitals	38%
Diagnostic Imaging Centers	24.5%
Research Laboratories & Academic Institutes	21.3%
Pharmaceutical & Biotechnology Companies	16.2%
Total	100.0%

Buyers of optical imaging are concentrated in hospitals, which account for 38% of 2026 sales, as cancer operations, retina services and research imaging cluster in large centres. Diagnostic imaging centers hold an estimated 24.5%, research laboratories and academic institutes 21.3%, and pharmaceutical and biotechnology companies 16.2%. Hospital eye services are investing in faster ways to handle images. Heidelberg Engineering presented a workflow described as the first truly automated DICOM workflow at ARVO 2026 [5]. Automated image handling reduces staff time per scan, and FMI expects hospitals to keep the lead through 2036.

• Hospital buyers include eye departments, cancer centres, dermatology units and academic medical centres.
• Pharmaceutical buyers use optical imaging in clinical trials. The clinical trials market is forecast to expand at a 4.3% CAGR from 2026 to 2036, which keeps a steady need for imaging endpoints.

What are the drivers, restraints, and opportunities in the optical imaging market?

Rising chronic eye disease and cancer case loads drive optical imaging demand. High system costs and the shift to longer-acting drugs restrain some purchases, and AI reading and intraoperative imaging open new opportunities.

• Driver: More people with diabetes, ageing eyes and cancer need repeated imaging to guide treatment.
• Restraint: Imaging systems are costly for smaller clinics, and longer-acting drugs can reduce visit frequency.
• Opportunity: AI reading tools and imaging in the operating room can widen use and raise value per system.

Chronic Disease Burden Drives Scan Volumes

Key drivers of growth begin with the steady rise in chronic disease that needs imaging follow-up. The International Diabetes Federation said 252 million adults with diabetes are not aware of the condition [1]. Every newly diagnosed patient needs regular retinal checks, so FMI sees screening programmes as the largest source of new OCT demand. Skin imaging adds a further route, with the dermatology devices market projected to grow at a 6.5% CAGR from 2026 to 2036.

System Costs and Dosing Shifts Restrain Purchases

Small clinics find advanced imaging systems costly, and treatment patterns are changing as well. Regeneron reported that US EYLEA net sales fell 45% to USD 412 million in the second quarter of 2026 [2]. Use of longer injection intervals can reduce the number of monitoring scans per patient. Suppliers will need to offset fewer visits with higher-value scans and software services.

AI Reading and Intraoperative Imaging Open New Demand

AI tools and new surgical uses can widen the optical imaging customer base. Perimeter Medical Imaging AI reported a statistically significant reduction in patients with residual cancer during the operation in a 206-patient trial [8]. Sales of optical imaging to hospitals outside ophthalmology gain from evidence of this type, which would diversify supplier income. Suppliers that combine optical hardware with validated AI will be best placed to capture these new uses.

Which country CAGRs are profiled in the optical imaging market?

Table 8: Country CAGR Comparison for the Optical Imaging Market (CAGR percentage), 2026 to 2036

Country	CAGR
India	5.9%
ASEAN	5.7%
China	5.3%
Spain	4.6%
Germany	4.2%
United States	3.8%
Japan	3.6%

How do country-level CAGRs compare in the optical imaging market?

India has the highest rate in the FMI table at 5.9%, which is 1.4 points above the 4.5% global rate, as eye hospitals widen diabetic screening. ASEAN comes next at 5.7% and China at 5.3%, both adding imaging capacity in private and public hospitals. Spain is just above the global rate at 4.6%. Germany at 4.2%, the United States at 3.8% and Japan at 3.6% fall below the global pace, as large installed bases leave growth to replacement.

• Eye hospital chains in India are adding OCT units for diabetic screening, which favours suppliers with lower-cost systems.
• Private hospitals across ASEAN are upgrading eye and cancer services, so distributors with service networks gain.
• China is expanding county-level hospital imaging, which raises demand for mid-range domestic and imported scanners.
• In Spain, regional health services are investing in retinal screening, which supports steady OCT orders.
• Germany has dense ophthalmology practices, so replacement and AI software upgrades drive purchases.
• Most US clinics already own OCT systems, so growth in the United States will come from AI tools and oncology uses.
• Clinics in Japan already have many OCT units, so most demand in Japan comes from replacing older systems.

Full report country CAGRs cover: a band from 3.6% in Japan to 5.9% in India across the seven profiled countries, with each remaining standard country shown in regional tables.

Country-wise Analysis

India Optical Imaging Market Outlook (2026 to 2036)

India has one of the largest diabetic populations, and private eye hospital chains are expanding quickly. Screening camps and tele-ophthalmology programmes add demand for portable and low-cost OCT. Wider screening supports an FMI growth rate of 5.9% for India, the highest among the seven countries in the table.

Key takeaway: Eye hospital chains in India are buying OCT units for diabetic screening, which gives India the fastest growth among the profiled countries.

ASEAN Optical Imaging Market Outlook (2026 to 2036)

Private hospitals in Thailand, Malaysia and other ASEAN countries are upgrading eye and cancer services for local and medical tourism patients. New hospitals buy complete imaging suites at opening. Hospital openings of this kind support a 5.7% CAGR for ASEAN.

Key takeaway: New private hospitals across ASEAN buy complete imaging suites at opening, which supports steady sales of OCT and other optical systems.

China Optical Imaging Market Outlook (2026 to 2036)

China is extending eye care and cancer imaging to smaller hospitals, and domestic makers offer lower-cost systems. Large patient volumes support both screening and research demand. Chinese purchases of optical imaging systems are likely to grow at a CAGR of about 5.3%.

Key takeaway: Chinese county-level hospitals are adding eye care and cancer imaging, and lower-cost domestic scanners help keep growth in China above the global rate.

Spain Optical Imaging Market Outlook (2026 to 2036)

Spanish regional health services are investing in retinal screening and cancer care. Public tenders favour multimodal systems that serve several departments. Demand in Spain is expected to grow at a 4.6% CAGR, slightly above the global rate.

Key takeaway: Spanish regional health services buy multimodal systems for retinal screening programmes, which keeps growth in Spain near the global pace.

Germany Optical Imaging Market Outlook (2026 to 2036)

Popularity of OCT in Germany reflects the presence of major optical suppliers and a dense network of ophthalmology practices. Carl Zeiss Meditec expects revenue to increase by a mid-single-digit percentage in fiscal 2025/26 [4]. Steady supplier growth reflects mature domestic demand, and Germany is projected to grow at a 4.2% CAGR.

Key takeaway: German ophthalmology practices mostly replace older scanners and add AI software, so purchases in Germany depend on replacement cycles more than new demand.

United States Optical Imaging Market Outlook (2026 to 2036)

Growth of the optical imaging market in the United States depends on a large installed base of OCT systems, and retinal drug use is shifting to longer-acting products. In the second quarter of 2026, Regeneron sold USD 596 million of EYLEA HD in the United States, 52% more than a year earlier [2]. Longer-acting drugs still need scans before each dose, so the United States is likely to grow at a 3.8% CAGR, with oncology and AI adding upside.

Key takeaway: US clinics already own many OCT systems, so new sales will come mainly from AI tools and new uses such as oncology imaging.

Japan Optical Imaging Market Outlook (2026 to 2036)

Japan has very high OCT availability in eye clinics and a stable, ageing patient base. Most purchases replace older scanners that reach the end of service life. FMI therefore expects Japan to grow at a 3.6% CAGR, the slowest rate among the seven countries.

Key takeaway: Japanese eye clinics already have very high OCT coverage, so most purchases in Japan will replace older scanners at the end of service life.

Who are the notable companies in the optical imaging market?

The profiled ophthalmic imaging groups are Carl Zeiss Meditec, Heidelberg Engineering, Topcon and Bioptigen. Coverage of specialist optical companies includes ChemImage, CytoViva, Michelson Diagnostics, Headwall Photonics, PerkinElmer, ASE Optics, Raytheon ELCAN Optical Technologies, Somanetics, St Jude Medical and Volcano Corporation.

The optical imaging market's top suppliers are led by eye care imaging groups, and specialist optical companies compete in research and surgical niches. Carl Zeiss Meditec reported fiscal 2024/25 EBITA of EUR 257.7 million [4]. Profits at that level fund steady product renewal, which keeps ZEISS ahead in clinic tenders. Heidelberg Engineering is pushing into digital surgical systems and showed the OPERA digital surgical microscope with intraoperative OCT at ARVO 2026 [5]. Surgical imaging gives OCT makers a second growth path beyond diagnostic clinics. The profiled companies fall into two groups, ophthalmic imaging companies and specialist optical companies.

• Ophthalmic imaging companies selling OCT and fundus systems: Carl Zeiss Meditec, Heidelberg Engineering, Topcon and Bioptigen.
• Specialist optical companies serving research, skin and surgical niches: ChemImage, CytoViva, Michelson Diagnostics, Headwall Photonics, PerkinElmer, ASE Optics, Raytheon ELCAN Optical Technologies, Somanetics, St Jude Medical and Volcano Corporation.

Competitive Benchmarking: Optical Imaging Market

Table 9: Competitive Benchmarking for the Optical Imaging Market (qualitative ratings), 2026

Company	OCT Systems	AI Software	Surgical Imaging	Recent Activity
Carl Zeiss Meditec	High	High	High	High
Heidelberg Engineering	High	Medium	Medium	High
Topcon	High	Medium	Low	Medium
Michelson Diagnostics	Medium	Low	Low	Low
Headwall Photonics	Low	Low	Medium	Low
ChemImage	Low	Medium	Medium	Low

Ratings compare the companies on OCT systems, AI software, surgical imaging and recent activity.

Key Developments in the Optical Imaging Market

• ZEISS introduced the ALTA DUO 300 on September 17, 2026, combining OCT and fundus photography [3]. Combined devices give clinics a reason to retire older single-mode units.
• Regeneron reported second-quarter 2026 results in July 2026, with US EYLEA HD net sales up 52% [2]. Longer-acting retinal drugs keep OCT at the centre of dosing decisions.
• At ARVO 2026 in May, Heidelberg Engineering showed a multimodal platform with ultra-high resolution OCT [5]. Higher resolution supports earlier detection of retinal disease.
• The American Cancer Society published Cancer Statistics 2026 in January 2026 [7]. Rising case counts sustain demand for cancer imaging tools.
• Carl Zeiss Meditec reported fiscal 2024/25 results on December 11, 2025 [4]. Steady ophthalmology growth confirms that clinics keep investing in equipment.
• In August 2025, ZEISS received a CE mark for CIRRUS PathFinder [6]. AI reading tools raise throughput on existing OCT scanners.

Key Players in the Optical Imaging Market

Ophthalmic Imaging Companies

• Carl Zeiss Meditec
• Heidelberg Engineering
• Topcon
• Bioptigen

Specialist Optical Companies

• ChemImage
• CytoViva
• Michelson Diagnostics
• Headwall Photonics
• PerkinElmer
• ASE Optics
• Raytheon ELCAN Optical Technologies
• Somanetics
• St Jude Medical
• Volcano Corporation

Optical Imaging Market - Report Scope

Table 10: Report Scope for the Optical Imaging Market (coverage fields and definitions), 2026 to 2036

Coverage field	Report scope
Market breakdown	Technology; application; end user; region
Quantitative units	USD billion
Market definition	Medical and research imaging systems that use light to image tissue, including optical coherence tomography, hyper-spectral and photo-acoustic imaging, Raman spectroscopy, diffuse optical tomography, super-resolution microscopy and terahertz tomography.
Regions covered	North America; Latin America; Western Europe; Eastern Europe; East Asia; South Asia and Pacific; Middle East and Africa
Countries covered	India; ASEAN; China; Spain; Germany; United States; Japan
Key companies profiled	Carl Zeiss Meditec, Heidelberg Engineering, Topcon, Bioptigen, ChemImage, CytoViva, Michelson Diagnostics, Headwall Photonics, PerkinElmer, ASE Optics, Raytheon ELCAN Optical Technologies, Somanetics, St Jude Medical, Volcano Corporation
Forecast period	2026 to 2036

Optical Imaging Market - Research Methodology

Table 11: Research Methodology for the Optical Imaging Market (research methods and approach), 2026 edition

Method	Approach
Data Sources	Company results, industry associations, government statistics and trade publications.
Desk Research	Desk research covers ophthalmic imaging, oncology imaging, AI software, device launches and disease burden.
Market Sizing	Market size combines system sales across technologies, applications and end users by region.
Data Validation	Figures are cross-checked across company, industry and government sources.

Optical Imaging Market by Segments

Optical Imaging Market segmented by Technology:

• Optical Coherence Tomography (OCT)
• Terahertz Tomography
• Raman Spectroscopy
• Photo-acoustic Imaging
• Diffuse Optical Tomography (DOT)
• Super-resolution Microscopy
• Hyper-spectral Imaging

Optical Imaging Market segmented by Application:

• Oncology
• Dermatology
• Drug Development
• Dentistry
• Neurology
• Ophthalmology

Optical Imaging Market segmented by End User:

• Hospitals
• Diagnostic Imaging Centers
• Research Laboratories & Academic Institutes
• Pharmaceutical & Biotechnology Companies

Optical Imaging Market by Region

• North America
  • United States
  • Canada
• Latin America
  • Brazil
  • Mexico
  • Argentina
  • Chile
• Western Europe
  • Germany
  • France
  • United Kingdom
  • Italy
  • Spain
  • Benelux
  • Nordics
• Eastern Europe
  • Poland
  • Czech Republic
  • Romania
  • Hungary
• East Asia
  • China
  • Japan
  • South Korea
• South Asia and Pacific
  • India
  • ASEAN
  • Australia and New Zealand
• Middle East and Africa
  • GCC Countries
  • South Africa
  • Türkiye
  • Israel

Research Sources and Bibliography

• [1] International Diabetes Federation. (2025, April 7). Over 250 million people worldwide unaware they have diabetes, according to new IDF research. https://idf.org/news-and-resources/news/idf-diabetes-atlas-11th-edition/
• [2] Regeneron Pharmaceuticals. (2026, July 30). Regeneron Reports Second Quarter 2026 Financial and Operating Results. https://www.biospace.com/press-releases/regeneron-reports-second-quarter-2026-financial-and-operating-results
• [3] Carl Zeiss Meditec. (2026, September 17). ZEISS expands retinal imaging portfolio with new ZEISS ALTA DUO 300. https://www.zeiss.com/meditec-ag/en/media-news/press-releases/2026/alta-duo-300.html
• [4] Carl Zeiss Meditec. (2025, December 11). Carl Zeiss Meditec closes fiscal year 2024/25 with solid growth in revenue and slight increase in EBITA. https://www.zeiss.com/meditec-ag/en/media-news/press-releases/2025/annual-report.html
• [5] Glance by Eyes On Eyecare. (2026, May 5). ARVO 2026: Heidelberg debuts new ophthalmic imaging and data management tech. https://glance.eyesoneyecare.com/stories/2026-05-05/arvo-2026-heidelberg-debuts-new-ophthalmic-imaging-and-data-management-tech/
• [6] MedTech Spectrum. (2025, August 22). ZEISS announces CE mark for CIRRUS PathFinder AI tool with automated OCT assessment. https://medtechspectrum.com/news/16/24725/zeiss-announces-ce-mark-for-cirrus-pathfinder-ai-tool-with-automated-oct-assessment-.html
• [7] OncLive. (2026, February 2). Latest ACS Cancer Statistics Report Outlines Notable Gains, Remaining Gaps Across Tumor Types. https://www.onclive.com/view/latest-acs-cancer-statistics-report-outlines-notable-gains-remaining-gaps-across-tumor-types
• [8] Ophthalmology Times. (2025, March 17). Perimeter submits Premarket Approval application with FDA for Perimeter B-Series OCT system. https://www.ophthalmologytimes.com/view/perimeter-submits-premarket-approval-application-with-fda-for-perimeter-b-series-oct-system-

This bibliography is provided for reader reference. The full report contains the complete reference list and detailed citations.

This Report Answers

• How big is the optical imaging market during 2026?
• What market size is projected by 2036?
• Which technology holds notable share?
• Which application holds notable share?
• Which countries have notable growth?
• Which companies are notable in the market?